Monte Rosa Therapeutics (GLUE) News Today $4.43 +0.02 (+0.45%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$4.43 0.00 (0.00%) As of 04/15/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Norges Bank Takes Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Norges Bank acquired a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 445,868 shares of the company's stock, valued at approximatelyApril 13 at 4:03 AM | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Drops By 12.6%Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 7,030,000 shares, a decline of 12.6% from the February 28th total of 8,040,000 shares. Based on an average daily trading volume, of 805,300 shares, the short-interest ratio is currently 8.7 days. Approximately 15.3% of the company's stock are sold short.April 3, 2025 | marketbeat.comVersant Venture Management LLC Purchases New Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)Versant Venture Management LLC acquired a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 5,652,922 shares of the company's stock, valued at aMarch 27, 2025 | marketbeat.comInsider Buying: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Buys 10,000 Shares of StockMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) Director Chandra P. Leo acquired 10,000 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average cost of $5.84 per share, with a total value of $58,400.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $58,400. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 26, 2025 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Acquires $58,400.00 in StockMarch 26, 2025 | insidertrades.comMonte Rosa Therapeutics: Exercise Extreme CautionMarch 25, 2025 | seekingalpha.comFY2029 Earnings Estimate for GLUE Issued By WedbushMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Equities researchers at Wedbush issued their FY2029 earnings per share estimates for shares of Monte Rosa Therapeutics in a research note issued to investors on Thursday, March 20th. Wedbush analyst R. Driscoll forecasts that the companyMarch 24, 2025 | marketbeat.comMonte Rosa Therapeutics price target raised to $17 from $15 at WedbushMarch 23, 2025 | markets.businessinsider.comMonte Rosa Therapeutics price target lowered to $10 from $11 at Wells FargoMarch 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comMonte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $10.00 at Wells Fargo & CompanyWells Fargo & Company decreased their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a report on Friday.March 22, 2025 | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)March 22, 2025 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)March 22, 2025 | markets.businessinsider.comMonte Rosa Therapeutics Earnings Call Highlights Progress and Strategic ShiftsMarch 21, 2025 | tipranks.comMonte Rosa Therapeutics (NASDAQ:GLUE) Earns Outperform Rating from WedbushWedbush reaffirmed an "outperform" rating and set a $17.00 target price (up from $15.00) on shares of Monte Rosa Therapeutics in a research report on Thursday.March 21, 2025 | marketbeat.comMonte Rosa Therapeutics (NASDAQ:GLUE) Posts Earnings Results, Beats Expectations By $0.50 EPSMonte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) announced its earnings results on Thursday. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.50.March 21, 2025 | marketbeat.comMonte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9MMarch 21, 2025 | markets.businessinsider.comMonte Rosa Therapeutics files $400M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comMonte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call TranscriptMarch 21, 2025 | seekingalpha.comMixed data results for two Monte Rosa molecular glue degradersMarch 21, 2025 | finance.yahoo.comMonte Rosa Therapeutics shares surge on strong Q4 revenue beatMarch 20, 2025 | in.investing.comMonte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 ProgramsMarch 20, 2025 | globenewswire.comBrokers Offer Predictions for GLUE FY2024 EarningsMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Analysts at Lifesci Capital issued their FY2024 EPS estimates for Monte Rosa Therapeutics in a note issued to investors on Wednesday, March 12th. Lifesci Capital analyst O. Mccammon anticipates that the company will post earnings per shaMarch 15, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform RecommendationMarch 13, 2025 | msn.comLifesci Capital Initiates Coverage on Monte Rosa Therapeutics (NASDAQ:GLUE)Lifesci Capital initiated coverage on Monte Rosa Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $19.00 price target for the company.March 13, 2025 | marketbeat.comMonte Rosa Therapeutics initiated with an Outperform at LifeSci CapitalMarch 12, 2025 | markets.businessinsider.comAlphaQuest LLC Takes $657,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)AlphaQuest LLC purchased a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 94,633 shares of the company's stock, valued at approximately $657,000. AlphaQuest LLC owned about 0.15% of MMarch 12, 2025 | marketbeat.comMonte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025March 11, 2025 | globenewswire.comMonte Rosa Therapeutics (GLUE) Projected to Post Earnings on ThursdayMonte Rosa Therapeutics (NASDAQ:GLUE) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comMonte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest UpdateMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 8,070,000 shares, a decline of 7.9% from the January 15th total of 8,760,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 7.0 days. Approximately 17.6% of the company's stock are sold short.February 18, 2025 | marketbeat.comShort Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Grows By 8.8%Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 9,140,000 shares, an increase of 8.8% from the December 31st total of 8,400,000 shares. Currently, 19.9% of the company's stock are sold short. Based on an average trading volume of 2,760,000 shares, the short-interest ratio is presently 3.3 days.February 2, 2025 | marketbeat.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short InterestMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 9,140,000 shares, an increase of 8.8% from the December 15th total of 8,400,000 shares. Currently, 19.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,760,000 shares, the days-to-cover ratio is currently 3.3 days.January 19, 2025 | marketbeat.comMonte Rosa Therapeutics provide corporate update, key milestones 2025January 11, 2025 | finance.yahoo.comMonte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025January 10, 2025 | markets.businessinsider.comMonte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comMonte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC grew its position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) by 23.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,044,689 sharesJanuary 5, 2025 | marketbeat.comMonte Rosa downgraded to Equal Weight from Overweight at Wells FargoDecember 20, 2024 | markets.businessinsider.comWells Fargo Downgrades Monte Rosa Therapeutics (GLUE)December 20, 2024 | msn.comMonte Rosa Therapeutics (NASDAQ:GLUE) Lowered to Equal Weight Rating by Wells Fargo & CompanyWells Fargo & Company lowered Monte Rosa Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $14.00 to $11.00 in a report on Thursday.December 19, 2024 | marketbeat.comMonte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of DirectorsDecember 13, 2024 | globenewswire.comMonte Rosa Therapeutics presents preclinical data on CDK2 degraderDecember 11, 2024 | markets.businessinsider.comMonte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersDecember 11, 2024 | globenewswire.comMonte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast CancerDecember 11, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Monte Rosa Therapeutics (GLUE) and CAMP4 Therapeutics Corporation (CAMP)December 6, 2024 | markets.businessinsider.comMonte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7% - Still a Buy?Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 8.7% Higher - What's Next?December 6, 2024 | marketbeat.comMonte Rosa Highlights Promising Results in Cancer StudyDecember 5, 2024 | markets.businessinsider.comMonte Rosa Therapeutics provides development progress on ongoing MRT-2359 studyDecember 5, 2024 | markets.businessinsider.comMonte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid TumorsDecember 5, 2024 | globenewswire.comMonte Rosa Therapeutics: A First AssessmentDecember 4, 2024 | seekingalpha.com Remove Ads Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address GLUE Media Mentions By Week GLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLUE News Sentiment▼1.550.79▲Average Medical News Sentiment GLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLUE Articles This Week▼32▲GLUE Articles Average Week Remove Ads Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IOVA News SNDX News WVE News COLL News ELVN News DYN News GPCR News ETNB News CMRX News CDMO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLUE) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLUE Stock Free GLUE Stock Alerts